Latest news with #ParseBiosciences'
Business Wire
10-07-2025
- Health
- Business Wire
Parse-Enabled Study Maps Neuronal Pathways with Potential Implications for Neurodegenerative Disease Research
SEATTLE--(BUSINESS WIRE)--Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced a groundbreaking study published in the journal Science that utilized Parse's single cell technology to uncover how signaling pathways drive the formation of diverse neuron cell subtypes. By linking specific signals to cell fate outcomes, this research provides a powerful framework for generating defined cell types in vitro, which has broad relevance to human biology, disease, and therapeutic development. 'Parse Biosciences' technology delivered the flexibility, scale, and quality to help us explore these complex cellular processes at a deeper level," states Barbara Treutlein, Head of the Quantitative Development Biology Lab at ETH Zurich. Principle investigators Dr. Barbara Treutlein, Head of the Quantitative Development Biology Lab at ETH Zurich, and Dr. Gray Camp, Group Leader at the Institute of Human Biology at Roche, led the experiment. Through an elegantly designed screening approach spanning 480 morphogens across 700,000 cells, the research team was able to explore how different morphogens interact with pro-neural transcription factors, thereby generating pure populations of different types of neurons from pluripotent stem cells. This work will guide and enable the neuroscience research community to direct and develop pure neuronal cell populations which will help expand our understanding of cell types and cell interactions implicated in neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS. 'We were genuinely surprised by the diversity of neurons that we generated, and the data allowed us to develop algorithms to learn how this diversity can arise,' states Treutlein. 'Parse Biosciences' technology delivered the flexibility, scale, and quality to help us explore these complex cellular processes at a deeper level.' 'The beauty of this work is that the underlying strategy, methods, and analyses can be adapted to program and explore any cell type and state, across organ systems and species,' states Camp. 'We are excited about what Parse's technology has enabled for this study.' 'We are thrilled to support this highly impactful study from Dr. Treutlein's and Dr. Camp's Labs and are eager to see how their findings inform the wider research community,' states Dr. Charlie Roco, Chief Technology Officer of Parse Biosciences. About Parse Biosciences Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. With technology developed at the University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $100 million in capital and is used by 3,000 customers across the world. Its growing portfolio of products includes Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR, Gene Select, and a solution for data analysis, Trailmaker™. Parse Biosciences is based in Seattle's vibrant South Lake Union district, where it recently expanded into a new headquarters and state-of-the-art laboratory. To learn more, please visit
Associated Press
25-02-2025
- Science
- Associated Press
Vevo Therapeutics Open Sources Tahoe-100M, the World's Largest Single-Cell Dataset, as the Inaugural Contribution to Arc Institute's New Virtual Cell Atlas
300 million single cell atlas now accessible to the scientific community comprised of Vevo's Tahoe-100M, mapping 60,000 drug-patient interactions, and Arc's AI-curated scBaseCamp 200 million cell dataset Generated using Vevo's Mosaic platform, Tahoe-100M leveraged Parse Biosciences' GigaLab for single cell sample preparation and Ultima Genomics for sequencing. PALO ALTO, Calif. and SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 /PRNewswire/ -- In a landmark move to advance AI-driven biological research, Arc Institute and Vevo Therapeutics announced today that they have partnered on the first release of the Arc Virtual Cell Atlas—the largest and most biologically diverse public resource for single-cell transcriptomic data across species, tissues, and experimental and perturbation conditions, starting with data from over 300 million unique cells. This data is open source and freely accessible via Arc's website as of February 25, 2025. The atlas currently includes single-cell gene expression data from two massive datasets: Vevo's Tahoe-100M, is the world's largest single-cell dataset, 50x larger than all public drug-perturbed data combined. It includes 100 million cells and maps 60,000 drug-patient interactions, measuring cellular response across 50 cancer cell lines to 1,200 drug perturbations. Tahoe-100M was generated using Vevo's Mosaic Technology, the first platform to make pan-cancer testing of drugs at single cell resolution scalable, and with support from Parse Biosciences' GigaLab leveraging its single-cell RNA sequencing capabilities. Arc's scBaseCamp is the first single-cell RNA sequencing data repository from public data to be curated and reprocessed at scale using AI agents. This gene expression data from another 200 million cells from 21 different species was sourced from public repositories and has been standardized to ensure interoperability for optimal use by machine learning models. 'What makes the Arc Virtual Cell Atlas particularly powerful is not just its scale, but that now researchers can analyze together both observational natural cell states and cells that have been deliberately perturbed by drugs or chemicals to see how they respond,' says Dave Burke ( @davey_burke) Arc Institute's Chief Technology Officer. 'We're grateful to partner with Vevo on our first release of this resource, leveraging their large-scale Tahoe-100M cell dataset, which is crucial for developing predictive models that can simulate cellular responses to perturbations, potentially reducing years of laboratory work to computational queries that take minutes.' 'Something extraordinary happened in the last few years: emergence of AI models that can predict protein structure and function,' says Nima Alidoust ( @nalidoust), Chief Executive Officer and Co-founder of Vevo Therapeutics. 'Our mission at Vevo is to go a huge step further: build AI models of human cells to predict how diseased cells interact with potential drug molecules.' 'These models need massive amounts of observational and drug-perturbed single-cell data, leaps beyond what is publicly available today,' says Johnny Yu, Chief Scientific Officer at Vevo. 'Our Mosaic platform overcomes this fundamental challenge; it can generate single-cell datasets such as Tahoe-100M at a scale that was not possible before.' 'We are open sourcing Tahoe-100M to help start a new movement in biological modeling that goes beyond us,' says Alidoust. 'Releasing it on Arc's Virtual Cell Atlas is the obvious choice as it aims to precisely do that.' The Arc Virtual Cell Atlas is now accessible on this portal: Arc's scBaseCamp Technical Report: About the Arc Institute The Arc Institute ( @arcinstitute) is an independent nonprofit research organization located in Palo Alto, California, that aims to accelerate scientific progress and understand the root causes of complex diseases. Arc's model gives scientists complete freedom to pursue curiosity-driven research agendas and fosters deep interdisciplinary collaboration. About Vevo Therapeutics Vevo Therapeutics is a biotechnology company using its in vivo drug discovery platform and next-generation AI models to uncover better drugs for more patients. The company's Mosaic platform is the first to make multi-patient drug screening data scalable, with single-cell precision, to better represent patient diversity in drug response. Vevo is using Mosaic to build the world's largest atlas of how drugs interact with patient cells and to train disease-relevant models of human cells for discovering novel targets and drugs undetectable by other technologies. Located in South San Francisco, CA, Vevo was founded by a team of inventors and thought leaders who have discovered drugs for 'undruggable' targets and invented novel methods in genomics, computational biology, and chemistry. Learn more at and follow us on LinkedIn and X.
